Condition: Myelodysplastic Syndromes · Sponsor: Beijing 302 Hospital
This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.
This description comes directly from the study's public registry record.
Bo Cai, MD · +861066947168 · caibo2008@163.com
Fei Peng, MD · +861066947180 · pengfei0118@foxmail.com
Always discuss trial participation with your own doctor first.
| Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07238686